Gut Feelings: Harnessing the Gut Microbiome to Manage Anxiety in Primary Care
Trillions of microbes inside us are not mere bystanders, but quiet architects of our moods.
Latest
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
✨ Onyx Summary Lexicon Pharmaceuticals presented new Phase 2b PROGRESS study data for its investigational AAK1 inhibitor, pilavapadin, at the NEUROdiab and EASD 2025 meetings, showing that the 10 mg once-daily dose achieved a statistically and clinically meaningful reduction in diabetic peripheral neuropathic pain while maintaining strong tolerability. The findings strengthen
Feeding the Future: Inside Aurélio Pavinato’s Big Dream for Agriculture
"Our dream is to positively impact upon future generations, by being the leader in global efficiency in the agricultural sector, and, above all, to respect the planet,” Dr. Aurélio Pavinato outlines why soil health and circularity are central to SLC Agrícola's long-term growth.
Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control
✨ Onyx Summary Cellares announced multiple technology partnerships to advance Cell Q™, the first fully automated, modular quality control platform designed to handle the commercial-scale throughput required for cell therapy manufacturing. By integrating best-in-class systems from partners like Tecan, Cytek, and Advanced Instruments, Cell Q sets a new standard for compliance,
Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
✨ Onyx Summary Piramal Pharma Solutions announced the acquisition of a Korsch XM-12 bilayer tablet press for its Morpeth, UK facility, enhancing its capabilities in oral solid and hormonal drug product development and manufacturing. The investment strengthens precision, flexibility, and containment in tablet production, supporting Piramal’s commitment to advanced drug
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial
✨ Onyx Summary SpyGlass Pharma appointed Anand Sundaram as Vice President, Head of Commercial, to lead launch strategy and build its commercial organization ahead of two planned Phase III trials for its sustained drug delivery platform. Sundaram brings extensive ophthalmic commercialization experience from Opthea, Iveric Bio, Novartis, and Genentech, strengthening SpyGlass’
From Pistons to Powertrains: The Road Ahead for Shriram Pistons & Rings
"Compressed natural gas requires a complete redesign of the pistons, the rings, and the engine valves - it’s not just a drop-in fuel,” Krishnakumar Srinivasan shows how SPR is future-proofing technology for CNG, ethanol, hybrids and EVs.
2025 Eisai R&D Day: Deepening Connections
✨ Onyx Summary MassBio will host the 2025 Eisai R&D Day on October 20 at Eisai’s G2D2 Center in Cambridge, featuring panel discussions, poster sessions, and networking to showcase Eisai’s R&D priorities in neuroscience, oncology, and global health. By fostering direct engagement between Eisai and
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
✨ Onyx Summary Avidity Biosciences closed a $690 million public offering of 17.25 million shares at $40 each, including the full exercise of underwriters’ option to purchase additional shares. The proceeds will support late-stage clinical development of its Antibody Oligonucleotide Conjugates (AOCs), preparation for multiple product launches, expansion of commercial
Built to Last: Why Acme Brick’s Ed Watson Believes Durability Is the Ultimate Sustainability
"If I were choosing a material for my home or business, I’d look at something that could last a century,” Ed Watson discusses Acme Brick’s future strategy: diversifying beyond brick, while preserving its legacy roots.
![Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma](/content/images/size/w1304/format/webp/2025/10/Perspective-1.png)
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
✨ Onyx Summary Perspective Therapeutics has dosed the first patient in a new Phase 1/2a cohort evaluating [212Pb]VMT01, its targeted alpha-particle therapy, in combination with Bristol Myers Squibb’s nivolumab (Opdivo®) for patients with metastatic melanoma. The expansion to a higher 3.0 mCi dose and combination arm marks
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
✨ Onyx Summary Ocugen has licensed exclusive rights to its investigational gene therapy OCU400 for retinitis pigmentosa to Kwangdong Pharmaceutical in South Korea, with upfront and milestone payments of up to $7.5 million, sales milestones tied to $180 million in projected 10-year sales, and a 25% royalty on net sales.
Alex M. Azar II Joins Guardant Health Board of Directors
✨ Onyx Summary Guardant Health announced the appointment of former U.S. Health and Human Services Secretary Alex M. Azar II to its board of directors, bringing extensive leadership experience from both government and the private sector. His addition underscores Guardant’s ambition to pair policy expertise with scientific innovation, strengthening
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
✨ Onyx Summary Kyverna Therapeutics will present interim Phase 2 data from the KYSA-6 study of its CD19 CAR T-cell therapy KYV-101 in generalized myasthenia gravis at the 2025 AANEM Annual Meeting. The results, part of a registrational Phase 2/3 study, will include efficacy and safety data for six patients
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
✨ Onyx Summary Belite Bio completed the last subject visit in its global Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1, which enrolled 104 adolescents across 11 jurisdictions (94 completed); the primary endpoint is the growth rate of atrophic lesions with safety/tolerability assessed. Top-line data are expected
Garbage into Gains: How RoadRunner is Using AI To Modernize Waste
"We know exactly how many containers are out there, how full they are and what’s in them, every day. That level of insight is mind-blowing,” Graham Rihn explains why precision data is reshaping the business of waste.